Synthesis and biological evaluation of new anticancer agents show VEGFR-2 inhibition in colon cancer cells, suggesting potential for targeted therapy.
Key Points
Compound 5h demonstrated potent VEGFR-2 inhibition, with an IC50 of 0.049 μM, comparable to sorafenib, indicating strong anticancer potential.
The synthesized morpholine-benzimidazole-oxadiazole derivatives showed selectivity against the HT-29 colon cancer cell line compared to normal cells.
Molecular docking studies confirmed effective interactions of compounds 5c, 5h, and 5j with the VEGFR-2 active site, suggesting stability and binding affinity.
This research highlights the potential of these novel derivatives as selective VEGFR-2 inhibitors for colon cancer treatment.